Clinical Trial Update: A Phase I Clinical Study of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies [Phase 1]

View source ↗

Summary

This document describes a Phase 1 clinical study of KSD-101 for relapsed or refractory EBV-associated hematological malignancies, with the trial status not yet …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Associated Hematological Malignancies

Drugs mentioned

• KSD-101

Snippet

Sponsor: Kousai Bio Co., Ltd. | Conditions: Relapsed or Refractory EBV-associated Hematological Malignancies | Phase 1 | Status: NOT_YET_RECRUITING